Larazotide
Tested in peopleGet notified when the evidence changes.
It has been tested in people, but it is not an approved medicine. The studies are usually small.
Compiled and reviewed by the PeptideSearch Editorial Team · Status checked 2026-08-04
Also called AT-1001 / Larazotide acetate / INN-202
Studied for tightening the gut lining in celiac disease. Reached late-stage human trials but missed its main goal.
Official status: Not nominated for 503A compounding · Checked 2026-08-04
Can a doctor prescribe this?
- Small pharmacy (503A)
- Never put forward to FDA
- Large outsourcing facility (503B)
- Never put forward to FDA
Investigational. Not approved and not on the compounding list.
503A is a pharmacy making a single prescription for one patient. 503B is a facility making batches. They are governed by separate lists. Where a category is shown, it is a position on the FDA's list of substances that have been put forward and are still being worked through — not the final list, which is set by rulemaking. Category 1 means the FDA does not plan to act against a pharmacy that makes it while the review runs.
Lab suppliers we list: 2
Doses used in research
Taken word for word from the studies and trials listed on this page. This is not a recommendation and not a dose for anyone to take.
- Study in peopleViral spike antigen clearance and augmented recovery in children with post-COVID multisystem inflammatory syndrome treated with larazotide.
Science translational medicine · 2025
- Animal study, rats or micePotassium-Competitive Acid Blocker Increases Ileal Permeability and Exacerbates Ileal Inflammation under Stress Conditions in a Mouse Model of Eosinophilic Enteritis.
Digestion · 2026
- Animal study, rats or micePreventive effects of Larazotide acetate (AT-1001) on non-alcoholic fatty liver diseases (NAFLD) in a mouse model.
Pediatrics and neonatology · 2026
- Animal study, rats or miceAntibacterial hyaluronic acid hydrogel with sustained release of larazotide as effective colitis treatment.
Journal of controlled release : official journal of the Controlled Release Society · 2025
- Animal study, rats or miceAmeliorative Effects of Larazotide Acetate on Intestinal Permeability and Bacterial Translocation in Acute Pancreatitis Model in Rats.
Digestive diseases and sciences · 2024
- Animal study, rats or miceTargeting endothelial tight junctions to predict and protect thoracic aortic aneurysm and dissection.
European heart journal · 2023
- Animal study, rats or miceSex-dependent Lupus <i>Blautia (Ruminococcus) gnavus</i> strain induction of zonulin-mediated intestinal permeability and autoimmunity.
Frontiers in immunology · 2022
- Animal study, rats or miceEffects of larazotide acetate, a tight junction regulator, on the liver and intestinal damage in acute liver failure in rats.
Human & experimental toxicology · 2021
- Animal study, rats or miceLarazotide acetate: a pharmacological peptide approach to tight junction regulation.
American journal of physiology. Gastrointestinal and liver physiology · 2021
- Lab dish studyBromelain and ficin proteolytic effects on gliadin cytotoxicity and expression of genes involved in cell-tight junctions in Caco-2 cells.
Amino acids · 2023
- Hypothesis, not a tested studyThe PAR2 Antagonist Larazotide Can Mitigate Acute Histamine-Stimulated Epithelial Barrier Disruption in Keratinocytes: A Potential Adjunct Treatment for Atopic Dermatitis.
JID innovations : skin science from molecules to population health · 2025
- Larazotide Acetate Protects the Intestinal Mucosal Barrier from Anoxia/Reoxygenation Injury via Various Cellular Mechanisms.
Biomedicines · 2025
- No abstract available, not yet classifiedTight junction regulation in celiac disease: role of larazotide acetate.
Minerva gastroenterology · 2022
- Review of earlier workCoeliac disease and the intestinal barrier: mechanisms of disruption and strategies for restoration.
Gut · 2026
- Review of earlier workIntegrated Role of Microbial, Fungal, and Plant-Derived Interventions in the Management of Celiac Disease: A Narrative Review.
Cureus · 2026
- Review of earlier workNew Therapeutic Challenges in Pediatric Gastroenterology: A Narrative Review.
Healthcare (Basel, Switzerland) · 2025
- Review of earlier workElucidating the Significance of Zonulin in the Pathogenesis of Chronic Inflammatory Disorders: Emphasis on Intestinal Barrier Function and Tight Junction Regulation.
Current medicinal chemistry · 2025
- Review of earlier workIs There a Future Without Gluten Restrictions for Celiac Patients? Update on Current Treatments.
Nutrients · 2025
- Review of earlier workZonulin as a Potential Therapeutic Target in Microbiota-Gut-Brain Axis Disorders: Encouraging Results and Emerging Questions.
International journal of molecular sciences · 2023
- Review of earlier workLarazotide acetate for treatment of celiac disease: A systematic review and meta-analysis of randomized controlled trials.
Clinics and research in hepatology and gastroenterology · 2022
- Review of earlier workThe Therapeutic use of the Zonulin Inhibitor AT-1001 (Larazotide) for a Variety of Acute and Chronic Inflammatory Diseases.
Current medicinal chemistry · 2021
- Review of earlier workCurrent pharmacological approaches and potential future therapies for Celiac disease.
European journal of pharmacology · 2021
Spot an error? corrections@peptidesearch.org